Asia Pacific Biosimilar Insulin Glargine and Lispro Market Report and Forecast 2024-2032

Asia Pacific Biosimilar Insulin Glargine and Lispro Market Outlook

The growth of the Asia Pacific biosimilar insulin glargine and lispro market size is driven by the growth in the global biosimilar insulin glargine and lispro market, which attained a value of USD 2,131.47 million in 2023. The global market is anticipated to grow at a CAGR of 14.3% during the forecast period of 2024-2032, likely to attain a value of USD 7,097.32 million by 2032.

Biosimilar Insulin Glargine and Lispro: Introduction

Biosimilar insulin is assumed as a potential alternate to expensive therapies. It is an injectable insulin which starts acting within fifteen minutes of injection and stays active till two to four hours after the injection. Due to the involvement of biosimilar insulin in healthcare, the market for biosimilar insulin glargine and lispro has gained significant traction over the last few years.

On the other hand, insulin lispro is a hormone which is used to lower the blood sugar levels. Insulin lispro acts fast, within fifteen minutes after the use. It takes at least two hours for it to strike the highest point and then it remains active for another two to four hours. This insulin is used in people who are suffering from diabetes mellitus including children. There are two type of insulin lispro that are being used in the treatment of type II diabetes in adults, type I diabetes in adults, and amongst children that are 3 years and older in age.

Asia Pacific Biosimilar Insulin Glargine and Lispro Market Analysis

The growth of the market is primarily driven by the rising prevalence of diabetes and other hormonal imbalance related disorders. Other key trends justifying the Asia Pacific biosimilar insulin glargine and lispro market growth include the rising healthcare sector, rising emphasis on better healthcare facilities, increasing prevalence of diabetes among the geriatric population. With the breakthrough advancement of technology and facilities in the healthcare sector, the market is anticipated to witness higher demand in the coming years.

Asia Pacific Biosimilar Insulin Glargine and Lispro Market Segmentations

Market Breakup by Type

• Branded Drug

• Biosimilar Drug

Market Breakup by Indications

• Type 1 Diabetes 

• Type 2 Diabetes

Market Breakup by Distribution Channel

• Hospitals 

• Commercial

• Store-Based

• Others

Market Breakup by Region

• China 

• Japan

• India 

• ASEAN 

• Australia 

• Others

Asia Pacific Biosimilar Insulin Glargine and Lispro Market Overview

The growth of the market is primarily being driven by the rising cases of diabetes across the Asia Pacific region, especially in India. Diabetes is a chronic autoimmune disease which can be a life-threatening disease if not taken care of. With diabetes, the production of insulin in the body almost or completely stops. Hence, it is important to fulfill the requirement of insulin externally. Due to the rising prevalence of diabetes and the rising number of fatalities across the region, the biosimilar insulin glargine and lispro market demand is constantly rising.

The other factor driving the market growth is the increasing geriatric population and unhealthy lifestyle including unhealthy eating habits, absence of active lifestyle, among others. According to the market segment by type, the market is divided into two categories which are branded and biosimilar drugs. Additionally, China is the leading country where the demand of the biosimilar insulin glargine and lispro is the highest in Asia Pacific.

Asia Pacific Biosimilar Insulin Glargine and Lispro Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Sanofi S.A. 

• Biocon Limited 

• Novo Nordisk A/S 

• Wockhardt Ltd. 

• Eli Lily and Company 

• Julphar Diabetes LLC 

• SAJA Pharmaceuticals 

• Gan & Lee Pharmaceutical Ltd. 

• Cipla Limited 

• Merck & Co.

Key Highlights of the Report